All In Biotech

Drug Trial Radar · NCT07927972

Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Subcutaneous Injections of Elamipretide in Pediatric Subjects With Barth Syndrome

A Phase 1 Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Injections of Elamipretide in Pediatric Subjects With Genetically Confirmed Barth Syndrome

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

6

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

May 2027

Study completion Jun 2027

Sponsor

Lead sponsor
Stealth BioTherapeutics Inc.Industry
Sponsor type
Industry
First posted
Nov 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 1, open-label trial will enroll approximately 6 subjects who have BTHS weighing between 7 and 30 kg. Subjects will receive a weight-based dose of elamipretide daily via SC injection for 4 weeks. PK samples will be collected on Day 1 and at week 4 to determine PK profile in BTHS patients weighing between 7 and 30kg.

Conditions

  • Barth Syndrome

Interventions

  • ElamipretideDrug

    SC injection daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum plasma concentration of elamipretide and its metabolitesTime frame: 24 hours
  2. Area under the plasma concentration time curve from 0 to 24 hoursTime frame: 24 hours

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama Birmingham Medical Center

    Birmingham, Alabama

  • Stanford University School of Medicine Pediatrics

    Palo Alto, California

  • OSF St. Francis Medical Center

    Peoria, Illinois

  • Children's Nebraska

    Omaha, Nebraska

  • Ichan School of Medicine at Mount Sinai

    New York, New York

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • UTSW: Children's Medical Center Pediatrics

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.